Global Meningococcal Vaccines Market - Forecasts to 2019: Sanofi, Novartis, GlaxoSmithKline, Pfizer, Serum Institute of India, JN-International, Nuron, Baxter and Biomed

DUBLIN, May 19, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/rd8s6p/meningococcal) has announced the addition of the "Global Meningococcal Vaccines Market - Forecasts to 2019: Sanofi, Novartis, GlaxoSmithKline, Pfizer, Serum Institute of India, JN-International, Nuron, Baxter and Biomed" report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769

Meningococcal disease caused by the bacterium Neisseria meningitidis is a life threatening condition which severely infects the meninges or the thin lining surrounding the brain and the spinal cord. Five out of many serogroups of the bacterium are responsible for the invasive meningococcal disease.

These serogroups are predominantly present only in humans in the dormant state and may eventually cause the diseased condition due to environmental or immunogenic factors. The disease is known to be contagious and its consequences can be fatal within 24 hours from the onset of symptoms. Prevalence of the serogroups responsible for the disease varies with age, time and geographical locations.

The global meningococcal vaccines market is segmented broadly into polysaccharide, conjugate and combination vaccines. These vaccine types are further segmented into different brands available in the market. Polysaccharide vaccines is the oldest type available in market since last three decades.

However, the presence and widespread use of conjugate vaccines has drastically reduced the incidences of bacterial meningitis due to the prolonged immunity achieved against the disease-causing serogroups, unlike polysaccharide vaccines which provide immunity for a very short period.

Combination vaccines against invasive meningococci in combination with other organisms such as pneumococcal and Haemophilus influenzae type B are considered as new weapons to fight against two bacterial infections. This has shown to reduce the number of injections needed to be administered when compared to their individual doses. Hence, combination vaccines are likely to have high growth in forthcoming years.

The notable pipeline vaccines against meningococcal disease include Bexsero by Novartis, MnB rLP2806 by Pfizer and NmVac4-DT by JN International Medical Corporation. Novartis in January 2013, received marketing authorization for Bexsero as the only vaccine against serogroup B, across the European Union, Canada and Australia, and has been currently filed for U.S. FDA licensure.

The rLP2806 vaccine, is currently in phase III clinical trials and has been granted Breakthrough Therapy Status by the U.S. FDA in 2014. NmVac4 DT, on the other hand, has been developed against the broad range of (quadrivalent) serogroups A, C, Y and W-135. Moreover, its manufacturer of the vaccine JN International Medical Corporation claims the vaccine to be animal component free, which is expected to be the major driver for its demand post market launch.

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Executive Summary

Chapter 3 Global Meningococcal Vaccines Market Overview

Chapter 4 Global Meningococcal Vaccines Market, by Type

Chapter 5 Global Meningococcal Vaccines Market, by Geography

Chapter 6 Competitive Landscape

Chapter 7 Recommendations

Chapter 8 Company Profiles

Companies Mentioned:

  • Baxter International, Inc.
  • Biomed Pvt. Ltd.
  • GlaxoSmithKline plc
  • JN-International Medical Corporation
  • Novartis International AG
  • Nuron Biotech, Inc.
  • Pfizer, Inc.
  • Sanofi SA
  • Serum Institute of India Ltd.

For more information visit http://www.researchandmarkets.com/research/rd8s6p/meningococcal

Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets



RELATED LINKS
http://www.researchandmarkets.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.